TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022
07/18/2022 - 04:05 PM
ANDOVER, Mass. July 18, 2022 Monday, August 1, 2022 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, followed by Conference ID: 626851. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact: Brian Johnston Investors@transmedics.com
https://www.prnewswire.com/news-releases/transmedics-to-report-second-quarter-2022-financial-results-on-august-1-2022-301587302.html
SOURCE TransMedics Group, Inc.
TMDX Rankings
#3404 Ranked by Stock Gains
TMDX Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Andover
About TMDX
transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
